Overview Phase 3 Papulopustular Rosacea Study Status: Completed Trial end date: 2013-08-01 Target enrollment: Participant gender: Summary The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months. Phase: Phase 3 Details Lead Sponsor: GaldermaGalderma R&DTreatments: Azelaic acid